Indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced cancers: 🔹 Ovarian Cancer: Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. 🔹 Therapy Goal: To maintain remission after response to platinum-based chemotherapy.

Dosage and administration

Packaging: 50 mg capsules. ⚠️ ADMINISTRATION PROTOCOL (Specific for Capsules): Total Daily Dose: 800 mg (400 mg twice daily). Per Dose: Take 8 capsules (50 mg each) at once, twice daily. Total Pills: 16 capsules per day. Timing & Food: Take on an empty stomach. Take at least 1 hour after a meal, and do not eat for 2 hours after taking the capsules. Administration: Swallow whole. Do not chew, dissolve, or open the capsules.

Hypersensitivity to Olaparib. Pregnancy and breastfeeding (embryo-fetal toxicity). Moderate to severe hepatic or renal impairment.

Common adverse reactions include: 🩸 Hematological: Anemia (low hemoglobin), neutropenia, thrombocytopenia. Monthly blood counts are recommended. 📉 Gastrointestinal: Nausea, vomiting (very common), diarrhea, loss of appetite, dysgeusia (taste distortion). 🌀 Physical: Fatigue (asthenia), headache, dizziness. Patients should be monitored for signs of blood toxicity (pale skin, shortness of breath).

Olanib 50 — Olaparib 50 mg, 112 pcs, Everest

100% original product

Active ingredient

Olaparib

Manufacturer

Everest

Dosage 50 mg

Dosage form Capsules

Capsules per pack 112

Olanib 50 (Olaparib) 50 mg Capsules

Name: Olanib 50
Brand: Everest
SKU: PROD-144
Price: 5054 UAH
Availability: InStock

5054₴ ~~5713₴~~ -12%

Olanib 50 mg (Olaparib) is a potent PARP inhibitor (poly ADP-ribose polymerase inhibitor) used for targeted cancer therapy.

Manufacturer: Everest Pharmaceuticals. Each pack contains 112 capsules. It works by exploiting DNA repair defects in tumors harboring BRCA mutations, causing synthetic lethality and cancer cell death.

Capsule Formulation Note:

This is the 50 mg capsule version. The dosing regimen involves a high pill burden (number of capsules) compared to the newer tablet formulations.

Indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced cancers:

🔹 Ovarian Cancer: Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
🔹 Therapy Goal: To maintain remission after response to platinum-based chemotherapy.

Packaging: 50 mg capsules.

⚠️ ADMINISTRATION PROTOCOL (Specific for Capsules):

Total Daily Dose: 800 mg (400 mg twice daily).
Per Dose: Take 8 capsules (50 mg each) at once, twice daily.
Total Pills: 16 capsules per day.
Timing & Food: Take on an empty stomach. Take at least 1 hour after a meal, and do not eat for 2 hours after taking the capsules.
Administration: Swallow whole. Do not chew, dissolve, or open the capsules.

Hypersensitivity to Olaparib.
Pregnancy and breastfeeding (embryo-fetal toxicity).
Moderate to severe hepatic or renal impairment.

Common adverse reactions include:

🩸 Hematological: Anemia (low hemoglobin), neutropenia, thrombocytopenia. Monthly blood counts are recommended.
📉 Gastrointestinal: Nausea, vomiting (very common), diarrhea, loss of appetite, dysgeusia (taste distortion).
🌀 Physical: Fatigue (asthenia), headache, dizziness.
Patients should be monitored for signs of blood toxicity (pale skin, shortness of breath).

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 18.03.2026